Le Lézard
Classified in: Health
Subject: LAW

ANDREOZZI + FOOTE CLIENT COMES FORWARD TO SEEK JUSTICE AGAINST RAMON GARCIA


PHILADELPHIA, May 8, 2024 /PRNewswire/ -- Andreozzi + Foote is deeply troubled by revelations of sexual abuse perpetrated by Ramon Garcia against patients at Carbon Health Urgent Care in Jenkintown and possibly other locations. Our client, Jane Doe, bravely stepped forward to share her story, shedding light on the egregious actions of Garcia, who allegedly used his position to commit acts of abuse under the guise of medical care.

Ramon Garcia, 33, a medical assistant at Carbon Health urgent care in Montgomery County, PA, is alleged to have misled and perpetrated sexual misconduct upon approximately a dozen area women. He is facing counts of aggravated indecent assault, multiple counts of indecent assault, invasion of privacy, impersonating a nurse, harassment, and other offenses.

The safety and well-being of patients should always be paramount, and any violation of trust by a healthcare professional is unacceptable. We commend our client for her courage in coming forward and urge other victims to speak out against any instances of abuse they may have experienced.

As a leading law firm representing victims of sexual abuse in civil cases, we are dedicated to seeking justice and accountability for those who have been harmed. We encourage victims to reach out to law enforcement to report any incidents of abuse, and we offer our compassion and support to those who may be considering legal action. Both victims and witnesses are encouraged to come forward.   

For more information or to speak with one of our attorneys, please contact Ben Andreozzi at [email protected] or 717-525-9124.

About Andreozzi + Foote:
Andreozzi + Foote is a Pennsylvania-based law firm focused on representing survivors of sexual abuse. The firm has successfully represented victims in some of the highest-profile child sexual abuse cases of our time. Andreozzi + Foote is committed to obtaining life-changing results for victims and their families.

SOURCE Andreozzi + Foote


These press releases may also interest you

at 22:00
Subang Jaya Medical Centre Applauded by Frost & Sullivan as the Best Hospital Company of the Year in Malaysia for the fourth consecutive year
Frost & Sullivan recently analyzed the hospital industry and noted that operational inefficiencies, workflow interruptions and shortage of skilled healthcare professionals are some key challenges faced by the healthcare industry. Based on its...

at 20:14
Innovent Announces Oral Presentations at ESMO Plenary and ESMO GI Congress on Clinical Data of IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2 ADC)
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 19:30
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP agilon health, inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm (AGL)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

More news about Health...


News published on and distributed by: